[go: up one dir, main page]

MX2016016288A - Polipeptidos efectores de la subunidad a de la toxina shiga resistentes a la disociacion por proteasa y moleculas dirigidas a las celulas que los comprenden. - Google Patents

Polipeptidos efectores de la subunidad a de la toxina shiga resistentes a la disociacion por proteasa y moleculas dirigidas a las celulas que los comprenden.

Info

Publication number
MX2016016288A
MX2016016288A MX2016016288A MX2016016288A MX2016016288A MX 2016016288 A MX2016016288 A MX 2016016288A MX 2016016288 A MX2016016288 A MX 2016016288A MX 2016016288 A MX2016016288 A MX 2016016288A MX 2016016288 A MX2016016288 A MX 2016016288A
Authority
MX
Mexico
Prior art keywords
cells
molecules
present
resistant
molecules directed
Prior art date
Application number
MX2016016288A
Other languages
English (en)
Other versions
MX373425B (es
Inventor
Poma Eric
Willert Erin
kim Jason
Higgins Jack
Original Assignee
Molecular Templates Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2015/012970 external-priority patent/WO2015113007A1/en
Application filed by Molecular Templates Inc filed Critical Molecular Templates Inc
Publication of MX2016016288A publication Critical patent/MX2016016288A/es
Publication of MX373425B publication Critical patent/MX373425B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/25—Shigella (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
    • C07K16/088—Varicella-zoster virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
    • C07K16/089—Cytomegalovirus
    • C07K16/1145—
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/20—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/286—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1077—Pentosyltransferases (2.4.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2497—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing N- glycosyl compounds (3.2.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/02—Pentosyltransferases (2.4.2)
    • C12Y204/02036—NAD(+)--diphthamide ADP-ribosyltransferase (2.4.2.36)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/02—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2) hydrolysing N-glycosyl compounds (3.2.2)
    • C12Y302/02022—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2) hydrolysing N-glycosyl compounds (3.2.2) rRNA N-glycosylase (3.2.2.22)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Neurology (AREA)

Abstract

La presente invención proporciona moléculas resistentes a la disociación por proteasa que comprenden los polipéptidos efectores de la toxina Shiga capaces de exhibir potentes funciones de la toxina Shiga (por ejemplo, el encaminamiento subcelular y la citotoxicidad). La presente invención también proporciona moléculas resistentes a la disociación por proteasa dirigidas a las células para dirigirse a tipos específicos de células, por ejemplo, las células infectadas o malignas. Ciertas moléculas de la presente invención son citotóxicas, y ciertas moléculas dirigidas a las células de la presente invención se puede utilizar para la aniquilación dirigida de tipos específicos de células, y para el tratamiento de una variedad de enfermedades, trastornos y afecciones, incluyendo cánceres, tumores, anormalidades del crecimiento, trastornos inmunológicos e infecciones microbianas. Ciertas moléculas dirigidas a las células de la invención exhiben una mejor tolerabilidad in vivo comparándose con las moléculas dirigidas a las células relacionadas que comprenden los polipéptidos efectores de la toxina Shiga de tipo silvestre sensibles a la disociación por proteasa. Las moléculas dirigidas a las células de la invención pueden suministrar materiales adicionales, tales como, por ejemplo, antígenos, agentes citotóxicos y agentes promotores de la detección, hacia el interior de las células objetivo.
MX2016016288A 2014-06-11 2015-06-10 Polipeptidos efectores de la subunidad a de la toxina shiga resistentes a la disociacion por proteasa y moleculas dirigidas a las celulas que los comprenden. MX373425B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462010918P 2014-06-11 2014-06-11
PCT/US2015/012970 WO2015113007A1 (en) 2014-01-27 2015-01-26 De-immunized shiga toxin a subunit effector polypeptides for applications in mammals
PCT/US2015/035179 WO2015191764A1 (en) 2014-06-11 2015-06-10 Protease-cleavage resistant, shiga toxin a subunit effector polypeptides and cell-targeted molecules comprising the same

Publications (2)

Publication Number Publication Date
MX2016016288A true MX2016016288A (es) 2017-10-12
MX373425B MX373425B (es) 2020-06-22

Family

ID=54834268

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016016288A MX373425B (es) 2014-06-11 2015-06-10 Polipeptidos efectores de la subunidad a de la toxina shiga resistentes a la disociacion por proteasa y moleculas dirigidas a las celulas que los comprenden.
MX2020004420A MX2020004420A (es) 2014-06-11 2016-12-08 Polipeptidos efectores de la subunidad a de la toxina shiga resistentes a la disociacion por proteasa y moleculas dirigidas a las celulas que los comprenden.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2020004420A MX2020004420A (es) 2014-06-11 2016-12-08 Polipeptidos efectores de la subunidad a de la toxina shiga resistentes a la disociacion por proteasa y moleculas dirigidas a las celulas que los comprenden.

Country Status (11)

Country Link
US (2) US10815469B2 (es)
EP (3) EP3950706A1 (es)
JP (3) JP6735237B2 (es)
KR (1) KR102496206B1 (es)
CN (2) CN113831416A (es)
AU (4) AU2015274647C1 (es)
CA (1) CA2947048C (es)
ES (2) ES2717751T3 (es)
IL (2) IL286804B (es)
MX (2) MX373425B (es)
WO (1) WO2015191764A1 (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL287490B (en) 2014-01-27 2022-08-01 Molecular Templates Inc Shiga toxin nonvaccine effector subunit-containing polypeptides for mammalian applications
US11142584B2 (en) 2014-03-11 2021-10-12 Molecular Templates, Inc. CD20-binding proteins comprising Shiga toxin A subunit effector regions for inducing cellular internalization and methods using same
CN113831416A (zh) 2014-06-11 2021-12-24 分子模板公司 耐受蛋白酶切割的志贺毒素a亚基效应子多肽和包含其的细胞靶向分子
ES2856457T3 (es) 2015-02-05 2021-09-27 Molecular Templates Inc Moléculas de unión a CD20 multivalentes que comprenden regiones efectoras de una subunidad de toxina shiga y composiciones enriquecidas de estas
CA2984635A1 (en) 2015-05-30 2016-12-08 Molecular Templates, Inc. De-immunized, shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same
MY197218A (en) 2015-07-06 2023-06-02 Regeneron Pharma Multispecific antigen-binding molecules and uses thereof
EP3325510A2 (en) 2015-07-26 2018-05-30 Molecular Templates, Inc. Cell-targeting molecules comprising shiga toxin a subunit effectors and cd8+ t-cell epitopes
WO2018106895A1 (en) * 2016-12-07 2018-06-14 Molecular Templates, Inc. Shiga toxin a subunit effector polypeptides, shiga toxin effector scaffolds, and cell-targeting molecules for site-specific conjugation
CN118562004A (zh) 2016-12-16 2024-08-30 蓝鳍生物医药公司 抗-含cub结构域蛋白1(cdcp1)抗体、抗体药物缀合物及其使用方法
AU2018213194B2 (en) 2017-01-25 2023-01-12 Molecular Templates, Inc. Cell-targeting molecules comprising de-immunized, Shiga toxin A Subunit effectors and CD8+ T-cell epitopes
US10961310B2 (en) 2017-03-15 2021-03-30 Pandion Operations, Inc. Targeted immunotolerance
SG11201909949XA (en) 2017-05-24 2019-11-28 Pandion Therapeutics Inc Targeted immunotolerance
NZ760232A (en) 2017-06-07 2023-05-26 Regeneron Pharma Compositions and methods for internalizing enzymes
WO2019023247A1 (en) 2017-07-25 2019-01-31 Immutics, Inc. TREATMENT OF CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND ITS LIGAND
AU2018330427A1 (en) * 2017-09-05 2020-04-02 GLAdiator Biosciences, Inc. Method of targeting exosomes
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174092B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
US12258597B2 (en) 2018-02-07 2025-03-25 Regeneron Pharmaceuticals, Inc. Methods and compositions for therapeutic protein delivery
AU2019257343A1 (en) 2018-04-17 2020-09-10 Molecular Templates, Inc. HER2-targeting molecules comprising de-immunized, Shiga toxin A Subunit scaffolds
WO2019222663A1 (en) 2018-05-17 2019-11-21 Regeneron Pharmaceuticals, Inc. Anti-cd63 antibodies, conjugates, and uses thereof
WO2020081493A1 (en) 2018-10-16 2020-04-23 Molecular Templates, Inc. Pd-l1 binding proteins
WO2020154475A1 (en) 2019-01-23 2020-07-30 Molecular Templates, Inc. Proteins comprising modified immunoglobulin variable light chains
CA3127624A1 (en) 2019-01-23 2020-07-30 Millennium Pharmaceuticals, Inc. Anti-cd38 antibodies
MX2021008790A (es) 2019-01-23 2021-08-24 Millennium Pharm Inc Proteinas de union a cd38 que comprenden efectores de la subunidad a de la toxina shiga desinmunizada.
CN116063505B (zh) 2019-01-30 2024-05-03 真和制药有限公司 抗gal3抗体及其用途
WO2020236875A1 (en) 2019-05-20 2020-11-26 Pandion Therapeutics, Inc. Madcam targeted immunotolerance
WO2021055816A1 (en) 2019-09-18 2021-03-25 Molecular Templates, Inc. Pd-l1 binding molecules comprising shiga toxin a subunit scaffolds
EP4031576A1 (en) 2019-09-18 2022-07-27 Molecular Templates, Inc. Pd-l1 binding molecules comprising shiga toxin a subunit scaffolds
US20210155671A1 (en) 2019-11-24 2021-05-27 Molecular Templates, Inc. Uses of cd20-binding molecules and additional therapeutic agents
US11981715B2 (en) 2020-02-21 2024-05-14 Pandion Operations, Inc. Tissue targeted immunotolerance with a CD39 effector
CN115956086A (zh) * 2020-05-06 2023-04-11 萨摩亚商柏沛生医股份有限公司 用于针对癌症及传染病的免疫疗法的融合蛋白
EP4157338A4 (en) 2020-05-26 2024-11-13 TrueBinding, Inc. METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING
EP4262858A1 (en) 2020-12-16 2023-10-25 Molecular Templates, Inc. Clinical methods for use of a pd-l1-binding molecule comprising a shiga toxin effector
EP4308242A1 (en) 2021-03-17 2024-01-24 Molecular Templates, Inc. Pd-l1 binding proteins comprising shiga toxin a subunit scaffolds and cd8+ t cell antigens
CN118103056A (zh) * 2021-11-05 2024-05-28 萨摩亚商柏沛生医股份有限公司 针对感染性动物疾病的免疫性融合蛋白
CN116240239B (zh) * 2023-04-18 2024-12-27 华东师范大学 程序可控的蛋白质快速分泌释放系统及其构建方法和应用

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5080898A (en) 1982-05-12 1992-01-14 The University Hospital Enzymatically active toxin coupled to a cell-specific ligand
US4894443A (en) 1984-02-08 1990-01-16 Cetus Corporation Toxin conjugates
US6022950A (en) 1984-06-07 2000-02-08 Seragen, Inc. Hybrid molecules having translocation region and cell-binding region
US5668255A (en) 1984-06-07 1997-09-16 Seragen, Inc. Hybrid molecules having translocation region and cell-binding region
US5091178A (en) 1986-02-21 1992-02-25 Oncogen Tumor therapy with biologically active anti-tumor antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5135736A (en) 1988-08-15 1992-08-04 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
CA2071969A1 (en) * 1989-12-22 1991-06-23 John R. Murphy Hybrid molecules having translocation region and cell-binding region
US5635384A (en) 1990-06-11 1997-06-03 Dowelanco Ribosome-inactivating proteins, inactive precursor forms thereof, a process for making and a method of using
US5621083A (en) 1991-11-04 1997-04-15 Xoma Corporation Immunotoxins comprising ribosome-inactivating proteins
US6146850A (en) 1991-11-04 2000-11-14 Xoma Corporation Proteins encoding gelonin sequences
JPH08510642A (ja) 1993-05-12 1996-11-12 ゾマ コーポレイション ゲロニンおよび抗体から成る免疫毒素
US5612474A (en) 1994-06-30 1997-03-18 Eli Lilly And Company Acid labile immunoconjugate intermediates
WO1996006641A1 (en) 1994-08-29 1996-03-07 Prizm Pharmaceuticals, Inc. Conjugates of vascular endothelial growth factor with targeted agents
JPH11506424A (ja) 1995-03-24 1999-06-08 オフィディアン ファーマシューティカルズ インコーポレーテッド ベロ毒素産生大腸菌に対する治療
US5667786A (en) 1995-06-07 1997-09-16 Novavax, Inc. Method for treating tumors with a toxin
CZ295838B6 (cs) 1996-09-09 2005-11-16 Zealand Pharma A/S Způsob výroby peptidů
AR010218A1 (es) 1996-09-10 2000-06-07 Military Henry M Jackson Foundation For The Advancement Of Una familia de proteinas bacterianas multi-unidad
US6306393B1 (en) 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
CA2222993A1 (en) 1998-02-04 1999-08-04 The Ontario Cancer Institute A method for using a ribosome-inactivating protein complex as a structural template and a molecular search engine in the design, construction and screening of combinatorial protein libraries
CA2329940A1 (en) 1998-06-05 1999-12-09 Mayo Foundation For Medical Education And Research Use of genetically engineered antibodies to cd38 to treat multiple myeloma
ES2205849T3 (es) * 1998-07-22 2004-05-01 Osprey Pharmaceuticals Limited Conjugados para tratar alteraciones inflamatorias y asociadas con daños tisulares.
US7157418B1 (en) 1998-07-22 2007-01-02 Osprey Pharmaceuticals, Ltd. Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
AU2004202331A1 (en) * 1998-07-22 2004-06-24 Osprey Pharmaceuticals Limited Methods and Compositions for Treating Secondary Tissue Damage and Other Inflammatory Conditions and Disorders
US6770456B1 (en) 1998-07-29 2004-08-03 Ludwig Institute For Cancer Research Endogenous retrovirus tumor associated nucleic acids and antigens
US8663692B1 (en) 1999-05-07 2014-03-04 Pharmasol Gmbh Lipid particles on the basis of mixtures of liquid and solid lipids and method for producing same
US7527787B2 (en) 2005-10-19 2009-05-05 Ibc Pharmaceuticals, Inc. Multivalent immunoglobulin-based bioactive assemblies
US6492498B1 (en) 1999-11-15 2002-12-10 Regents Of The University Of Minnesota Multimeric immunotoxins
US7267973B2 (en) 2000-03-22 2007-09-11 Sibtech, Inc. Nucleic acids encoding recombinant proteins containing Shiga-like toxin and vascular endothelial growth factor
US20010031485A1 (en) 2000-03-22 2001-10-18 Sibtech, Inc. Recombinant proteins containing Shiga-like toxin and vascular endothelial growth factor fragments
EP2857516B1 (en) 2000-04-11 2017-06-14 Genentech, Inc. Multivalent antibodies and uses therefor
DE60333004D1 (de) 2002-02-04 2010-07-29 Yoshida Hideo Antikrebsmittel mit verotoxinvarianten
DE60203491D1 (de) * 2002-08-02 2005-05-04 Inst Curie Paris Shiga-Toxin-Untereinheit B als Vektor zur Diagnose von Tumoren und zur Arzneimittelverabreichung an GB3-exprimierenden Tumoren
EP1572744B1 (en) 2002-12-16 2010-06-09 Genentech, Inc. Immunoglobulin variants and uses thereof
AU2003303374A1 (en) 2002-12-20 2004-07-22 The Johns Hopkins University Treatment of metastatic cancer with the b-subunit of shiga toxin
US7834258B2 (en) 2003-06-30 2010-11-16 Mu-Hyeon Choe Dimer of chimeric recombinant binding domain-functional group fusion formed via disulfide-bond-bridge and the processes for producing the same
US8147832B2 (en) 2003-08-14 2012-04-03 Merck Patent Gmbh CD20-binding polypeptide compositions and methods
US7585942B2 (en) 2003-11-25 2009-09-08 Anjin Corporation Diphtheria toxin variant
US7982011B2 (en) 2003-11-25 2011-07-19 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Mutated anti-cd22 antibodies and immunoconjugates
US20070298434A1 (en) 2004-03-26 2007-12-27 Jean Gariepy Library of Toxin Mutants, and Methods of Using Same
WO2006099875A1 (en) 2005-03-23 2006-09-28 Genmab A/S Antibodies against cd38 for treatment of multiple myeloma
US7771955B2 (en) 2005-06-09 2010-08-10 University Of Maryland Affinity membrane for capture of a target biomolecule and formation thereof by site-directed immobilization of a capture biomolecule
HRP20151102T1 (xx) 2005-07-01 2015-11-20 E. R. Squibb & Sons, L.L.C. Humana monoklonska antitijela za ligand programirane smrti 1 (pd-l1)
FI20055417A0 (fi) 2005-07-20 2005-07-20 Glykos Finland Oy Syöpäpesifiset glykaanit ja niiden käyttö
NZ565173A (en) 2005-07-25 2012-01-12 Emergent Product Dev Seattle Single dose use of CD20 scFv for rheumatoid arthritis
CN101384614A (zh) * 2005-08-15 2009-03-11 加利福尼亚大学董事会 Vegf活化的fas配体
ES2493465T3 (es) 2005-09-26 2014-09-11 Molecular Templates, Inc. Biblioteca a partir de toxinas mutantes y procesos de utilización de la misma
GB0524788D0 (en) 2005-12-05 2006-01-11 Affibody Ab Polypeptides
JP2009520468A (ja) 2005-12-23 2009-05-28 ヴィヴェンティア バイオテック インコーポレーティッド 融合タンパク質ライブラリーの作製法およびスクリーニング法、ならびにそれらの使用
ES2532985T3 (es) 2006-02-16 2015-04-06 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Proteínas quiméricas de toxoide de Shiga
JP4954293B2 (ja) * 2006-12-29 2012-06-13 オスプレイ・ファーマシューティカルズ・ユーエスエイ・インコーポレイテッド 改変毒素を選択および生産する方法、改変毒素を含む複合体、およびそれらの使用
AU2008279550B2 (en) 2007-06-21 2012-08-09 Angelica Therapeutics, Inc. Modified toxins
US9364557B2 (en) 2007-08-01 2016-06-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Fold-back diabody diphtheria toxin immunotoxin and methods of use
SI2197903T1 (sl) 2007-09-04 2015-02-27 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services National Institutes of Health Office of Technology Transfer 6011 Izbris v obmoäśju ii pseudomonas eksotoksina a, ki zniĺ˝uje ne-specifiäśno toksiäśnost
WO2009064815A1 (en) 2007-11-13 2009-05-22 The Scripps Research Institute Production of cytotoxic antibody-toxin fusion in eukaryotic algae
MX2010005783A (es) 2007-11-27 2010-08-10 Ablynx Nv Secuencias de aminoacidos dirigidas contra citoquinas heterodimericas y/o sus receptores y polipeptidos que comprenden las mismas.
WO2009078766A1 (en) 2007-12-17 2009-06-25 Telefonaktiebolaget Lm Ericsson (Publ) Multi-antenna receiver interference cancellation method and apparatus
US8470314B2 (en) 2008-02-29 2013-06-25 Angelica Therapeutics, Inc. Modified toxins
US7919273B2 (en) 2008-07-21 2011-04-05 Immunomedics, Inc. Structural variants of antibodies for improved therapeutic characteristics
WO2010033229A2 (en) 2008-09-22 2010-03-25 Calmune Corporation Methods and vectors for display of molecules and displayed molecules and collections
AU2010206800B2 (en) 2009-01-23 2016-06-30 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Methods and compositions based on Shiga toxin type 2 protein
WO2010122460A1 (en) 2009-04-20 2010-10-28 Pfizer Inc. Control of protein glycosylation and compositions and methods relating thereto
US20120258104A1 (en) 2009-07-22 2012-10-11 Cenix Bioscience Gmbh Delivery System and Conjugates For Compound Delivery Via Naturally Occurring Intracellular Transport Routes
EP2371864A1 (en) 2010-03-23 2011-10-05 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
JP6320753B2 (ja) 2010-05-27 2018-05-09 ゲンマブ エー／エス Ｈｅｒ２に対するモノクローナル抗体
GB201013989D0 (en) 2010-08-20 2010-10-06 Univ Southampton Biological materials and methods of using the same
PL219845B1 (pl) 2011-01-05 2015-07-31 Adamed Spółka Z Ograniczoną Odpowiedzialnością Przeciwnowotworowe białko fuzyjne
EP2476441A1 (en) * 2011-01-13 2012-07-18 Universitat Autònoma De Barcelona Methods and reagents for efficient and targeted delivery of therapeutic molecules to CXCR4 cells
CA2825023A1 (en) 2011-01-26 2012-08-02 Cenix Bioscience Gmbh Delivery system and conjugates for compound delivery via naturally occurring intracellular transport routes
CN103458930B (zh) * 2011-02-01 2019-10-15 健玛保 针对cd74的人抗体和抗体-药物缀合物
US8895006B2 (en) 2011-03-04 2014-11-25 Rutgers, The State University Of New Jersey Ricin ribosome binding protein compositions and methods of use thereof
PH12013502264A1 (en) 2011-05-06 2019-03-22 Us Gov Health & Human Services Recombinant immunotoxin targeting mesothelin
PL397167A1 (pl) * 2011-11-28 2013-06-10 Adamed Spólka Z Ograniczona Odpowiedzialnoscia Przeciwnowotworowe bialko fuzyjne
CA2865243A1 (en) 2012-02-23 2013-08-29 President And Fellows Of Harvard College Modified microbial toxin receptor for delivering agents into cells
CA2902324A1 (en) 2013-03-12 2014-10-09 Molecular Templates, Inc. Cd20-binding immunotoxins for inducing cellular internalization and methods using same
GB2519786A (en) 2013-10-30 2015-05-06 Sergej Michailovic Kiprijanov Multivalent antigen-binding protein molecules
US20160177284A1 (en) 2014-01-27 2016-06-23 Molecular Templates, Inc. Cell-targeted molecules comprising amino-terminus proximal or amino-terminal shiga toxin a subunit effector regions
US20210138076A2 (en) 2014-01-27 2021-05-13 Molecular Templates, Inc. Cell-targeting molecules comprising shiga toxin a subunit effectors and cd8+ t-cell epitopes
IL287490B (en) 2014-01-27 2022-08-01 Molecular Templates Inc Shiga toxin nonvaccine effector subunit-containing polypeptides for mammalian applications
WO2015120058A2 (en) 2014-02-05 2015-08-13 Molecular Templates, Inc. Methods of screening, selecting, and identifying cytotoxic recombinant polypeptides based on an interim diminution of ribotoxicity
US11142584B2 (en) 2014-03-11 2021-10-12 Molecular Templates, Inc. CD20-binding proteins comprising Shiga toxin A subunit effector regions for inducing cellular internalization and methods using same
CN113831416A (zh) 2014-06-11 2021-12-24 分子模板公司 耐受蛋白酶切割的志贺毒素a亚基效应子多肽和包含其的细胞靶向分子
EP3157958B1 (en) 2014-06-18 2020-05-06 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Car-expressing nk-92 cells as cell therapeutic agents
CN105713087B (zh) 2014-11-12 2020-05-08 北京康乐卫士生物技术股份有限公司 人乳头瘤病毒58型单克隆抗体及其应用
ES2856457T3 (es) 2015-02-05 2021-09-27 Molecular Templates Inc Moléculas de unión a CD20 multivalentes que comprenden regiones efectoras de una subunidad de toxina shiga y composiciones enriquecidas de estas
KR20240135877A (ko) 2015-03-04 2024-09-12 아이쥐엠 바이오사이언스 인코포레이티드 Ｃｄ20 결합 분자 및 그의 용도
CN107873128B (zh) 2015-04-07 2021-06-25 安博科技有限公司 在云端的多边界防火墙
CA2984635A1 (en) 2015-05-30 2016-12-08 Molecular Templates, Inc. De-immunized, shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same
EP3325510A2 (en) 2015-07-26 2018-05-30 Molecular Templates, Inc. Cell-targeting molecules comprising shiga toxin a subunit effectors and cd8+ t-cell epitopes
US11326182B2 (en) 2016-04-29 2022-05-10 Voyager Therapeutics, Inc. Compositions for the treatment of disease
CA3041078A1 (en) 2016-10-30 2018-05-03 Shanghai Henlius Biotech, Inc. Anti-pd-l1 antibodies and variants
WO2018106895A1 (en) 2016-12-07 2018-06-14 Molecular Templates, Inc. Shiga toxin a subunit effector polypeptides, shiga toxin effector scaffolds, and cell-targeting molecules for site-specific conjugation
US11597914B2 (en) 2016-12-26 2023-03-07 Dankook University Cheonan Campus Industry Academic Cooperation Foundation IgG type monoclonal antibodies specifically binding to odontoblast surface
AU2018213194B2 (en) 2017-01-25 2023-01-12 Molecular Templates, Inc. Cell-targeting molecules comprising de-immunized, Shiga toxin A Subunit effectors and CD8+ T-cell epitopes

Also Published As

Publication number Publication date
AU2015274647B2 (en) 2019-08-22
ES2919749T3 (es) 2022-07-28
JP2022088518A (ja) 2022-06-14
EP3514168A1 (en) 2019-07-24
JP2020180154A (ja) 2020-11-05
US20210017512A1 (en) 2021-01-21
AU2019240612B2 (en) 2020-09-17
JP2017524342A (ja) 2017-08-31
KR102496206B1 (ko) 2023-02-06
US10815469B2 (en) 2020-10-27
AU2015274647C1 (en) 2020-01-30
IL286804B (en) 2022-08-01
EP3950706A1 (en) 2022-02-09
MX373425B (es) 2020-06-22
JP6735237B2 (ja) 2020-08-05
EP3137488A1 (en) 2017-03-08
CA2947048A1 (en) 2015-12-17
IL286804A (en) 2021-10-31
ES2717751T3 (es) 2019-06-25
AU2022201220A1 (en) 2022-03-17
CN113831416A (zh) 2021-12-24
EP3137488B1 (en) 2019-01-02
WO2015191764A1 (en) 2015-12-17
MX2020004420A (es) 2020-07-29
EP3514168B1 (en) 2021-09-01
CA2947048C (en) 2023-10-17
CN106604934A (zh) 2017-04-26
AU2019240612A1 (en) 2019-10-17
AU2020260425A1 (en) 2020-11-26
AU2020260425B2 (en) 2021-12-16
US20170101636A1 (en) 2017-04-13
KR20170010896A (ko) 2017-02-01
IL249006B (en) 2021-10-31
IL249006A0 (en) 2017-01-31
AU2015274647A1 (en) 2016-12-15
JP7054948B2 (ja) 2022-04-15

Similar Documents

Publication Publication Date Title
MX2016016288A (es) Polipeptidos efectores de la subunidad a de la toxina shiga resistentes a la disociacion por proteasa y moleculas dirigidas a las celulas que los comprenden.
CY1124541T1 (el) Πρωτεϊνες που περιλαμβανουν αμινο-τερματικες εγγυτερες τελεστικες περιοχες υπομοναδων τοξινης shiga α και περιοχες δεσμευσης τυπου-ανοσοσφαιρινων στοχευσης-κυτταρων δυναμενες της κατα συγκεκριμενο τροπο δεσμευσης cd38
DOP2020000050A (es) Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismos
MX2021005131A (es) Polipeptidos que administran epitopos de cmh de clase i.
CO2019000386A2 (es) Compuestos heterocíclicos como inmunomoduladores
PE20190515A1 (es) Peptidos modificados de auristatina y conjugados anticuerpo-farmaco de los mismos
CY1126074T1 (el) Περιοχες gla ως παραγοντες στοχευσης
MX2018005315A (es) Composiciones y metodos para el tratamiento del cancer.
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
UY36075A (es) Derivados de tubulisina
CL2016002027A1 (es) Ciclopropilamina como inhibidor de la lsd1
CL2015003395A1 (es) Derivados pirazolopirrolidina y su uso en el tratamiento de la enfermedad
UY34657A (es) ?derivados macrocíclicos para el tratamiento de enfermedades?.
MX2017002656A (es) Compuestos que inhiben la proteína mcl-1.
MX377916B (es) Compuestos 4-amino-imidazoquinolina.
EA201700181A1 (ru) Композиции аденозиндеаминазы-2 (ада-2), их варианты и способы использования
MX391015B (es) Composiciones de nanoparticulas y usos de las mismas
AR104664A1 (es) Conjugados de fármacos con anticuerpos contra la cadherina 6 (anti-cdh6)
CO6670575A2 (es) Aminopirazoloqinazolinas sustituidas, útiles en el tratamiento de enfermedades proliferativas y composiciones farmaceúticas que las continen
CL2016002091A1 (es) Compuesto de triazina y su uso para fines medicinales
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
CL2016003260A1 (es) Profármacos de gemcitabina
MX2021007235A (es) Tubulisinas y conjugados de proteina-tubulisina.
MX366365B (es) Peptidos de kntc2 y vacunas que los contienen.
CO2020016131A2 (es) Agonistas de tlr7

Legal Events

Date Code Title Description
FG Grant or registration